All Stories

Denali's ALS drug fails to redeem itself, missing key biomarker in trial extension

Denali Therapeutics’ amyotrophic lateral sclerosis drug has racked up another clinical miss this year, leaving the company to mull the asset’s future.

Mar 6, 2025 - 14:27
 0
Denali's ALS drug fails to redeem itself, missing key biomarker in trial extension
Denali Therapeutics’ amyotrophic lateral sclerosis drug has racked up another clinical miss this year, leaving the company to mull the asset’s future.
Read More

Tags:

Previous Article

FedEx Driver Rescued By Boat After Delivery Truck Stranded By Rising Tides

Next Article

Human medicines European public assessment report (EPAR): Eltrombopag Viatris, e...

Related Posts

Fierce Biotech Layoff Tracker 2025: Cargo lays off 90% of staff; Empress halves workforce

Fierce Biotech Layoff Tracker 2025: Cargo lays off 90% ...

Mar 19, 2025  0

Fierce Biotech Fundraising Tracker '25: Glycomine gathers $115M series C; Attovia attracts $90M series C

Fierce Biotech Fundraising Tracker '25: Glycomine gathe...

Apr 16, 2025  0

Intuitive snags FDA clearance for its single-port surgical stapler

Intuitive snags FDA clearance for its single-port surgi...

Apr 10, 2025  0